CompletedPhase 1NCT03246659

Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC

Studying Medullary thyroid carcinoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Paola Anna Erba
Principal Investigator: Paola Anna Erba, Professor
Azienda Ospedaliero, Universitaria Pisana
Intervention: 111In-CP04(drug)
Enrollment: 16 target
Eligibility: 18 years · All sexes
Timeline: 2016 – 2018

Study locations (5)

Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck, Austria
Department of Nuclear Medicine, University Hospital Freiburg, Freiburg im Breisgau, Germany
Erasmus University Rotterdam, Rotterdam, Netherlands
Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland
Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia

Collaborators

Jagiellonian University · University Hospital Freiburg · Medical University Innsbruck · University Medical Centre Ljubljana · NATIONAL CENTRE FOR NUCLEAR RESEARCH, Poland · Erasmus Medical Center · INRASTES, NCSR Demokritos, Athens, Greece

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03246659 on ClinicalTrials.gov

Other trials for Medullary thyroid carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Medullary thyroid carcinoma →

← Back to all trials